Variant report
Variant | nsv961573 |
---|---|
Chromosome Location | chr2:234655021-234655848 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:4)
- CpG islands (count:61)
- Chromatin interactive region (count:2)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
(count:4 , 50 per page) page:
1
No. | Transcrition factor | Chromosome Location | Cell Line | Cell type | Cell Stage | Matched TF binding sites |
---|---|---|---|---|---|---|
1 | POLR2A | chr2:234655118-234655244 | A549 | lung: | n/a | n/a |
2 | POLR2A | chr2:234655122-234655288 | A549 | lung: | n/a | n/a |
3 | RFX5 | chr2:234655392-234655393 | HepG2 | liver: | n/a | n/a |
4 | TEAD4 | chr2:234655225-234655511 | ECC-1 | luminal epithelium: | n/a | n/a |
No. | Chromosome Location | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr2:234655709-234655759 | SK-N-SH | brain: | n/a |
2 | chr2:234655709-234655759 | AG04449 | skin: | fetal |
3 | chr2:234655709-234655759 | HNPCEpiC | eye: | n/a |
4 | chr2:234655709-234655759 | HCT-116 | colon: | n/a |
5 | chr2:234655709-234655759 | MCF-7 | breast: | n/a |
6 | chr2:234655709-234655759 | H1-hESC | embryonic stem cell: | embryo |
7 | chr2:234655709-234655759 | HCM | heart: | n/a |
8 | chr2:234655709-234655759 | Hepatocyte | liver: | n/a |
9 | chr2:234655709-234655759 | AG09309 | skin: | n/a |
10 | chr2:234655709-234655759 | HL-60 | blood: | n/a |
11 | chr2:234655709-234655759 | AG10803 | skin: | n/a |
12 | chr2:234655709-234655759 | GM12892 | blood: | n/a |
13 | chr2:234655709-234655759 | RPTEC | kidney: | n/a |
14 | chr2:234655709-234655759 | CMK | blood: | n/a |
15 | chr2:234655709-234655759 | PFSK-1 | brain: | n/a |
16 | chr2:234655709-234655759 | LNCaP | prostate: | n/a |
17 | chr2:234655709-234655759 | HRPEpiC | eye: | n/a |
18 | chr2:234655709-234655759 | PANC-1 | pancreas: | n/a |
19 | chr2:234655709-234655759 | HCF | heart: | n/a |
20 | chr2:234655709-234655759 | NHBE | bronchial: | n/a |
21 | chr2:234655709-234655759 | K562 | blood: | n/a |
22 | chr2:234655709-234655759 | HepG2 | liver: | n/a |
23 | chr2:234655709-234655759 | A549 | lung: | n/a |
24 | chr2:234655709-234655759 | ECC-1 | luminal epithelium: | n/a |
25 | chr2:234655709-234655759 | AG09319 | gingival: | n/a |
26 | chr2:234655709-234655759 | SK-N-SH_RA | brain: | n/a |
27 | chr2:234655709-234655759 | HCPEpiC | choroid plexus: | n/a |
28 | chr2:234655709-234655759 | T-47D | breast: | n/a |
29 | chr2:234655709-234655759 | SAEC | small airway: | n/a |
30 | chr2:234655709-234655759 | Jurkat | blood: | n/a |
31 | chr2:234655709-234655759 | AoSMC | blood vessel: | n/a |
32 | chr2:234655709-234655759 | HMEC | breast: | n/a |
33 | chr2:234655709-234655759 | HAEpiC | amniotic membrane: | n/a |
34 | chr2:234655709-234655759 | Hela-S3 | cervix: | n/a |
35 | chr2:234655709-234655759 | SKMC | muscle: | n/a |
36 | chr2:234655709-234655759 | HEK293 | kidney: | embryo |
37 | chr2:234655709-234655759 | NB4 | blood: | n/a |
38 | chr2:234655709-234655759 | BE2_C | brain: | n/a |
39 | chr2:234655709-234655759 | SK-N-MC | brain: | n/a |
40 | chr2:234655709-234655759 | HEEpiC | esophagus: | n/a |
41 | chr2:234655709-234655759 | NT2-D1 | testis: | n/a |
42 | chr2:234655709-234655759 | IMR90 | lung: | fetal |
43 | chr2:234655709-234655759 | ProgFib | skin: | n/a |
44 | chr2:234655709-234655759 | PrEC | prostate: | n/a |
45 | chr2:234655709-234655759 | ovcar-3 | ovarian: | n/a |
46 | chr2:234655709-234655759 | HUVEC | blood vessel: | n/a |
47 | chr2:234655709-234655759 | HRCEpiC | kidney: | n/a |
48 | chr2:234655709-234655759 | MCF10A-Er-Src | breast: | n/a |
49 | chr2:234655709-234655759 | HPAEpiC | pulmonary alveolar: | n/a |
50 | chr2:234655709-234655759 | GM19239 | blood: | n/a |
(count:2 , 50 per page) page:
1
No data |
No data |
No data |
Variant related genes | Relation type |
---|---|
UGT1A2P | TF binding region |
ENSG00000248705 | TF binding region |
DNAJB3 | TF binding region |
UGT1A2P | CpG island |
ENSG00000248705 | CpG island |
DNAJB3 | CpG island |
ENSG00000242515 | chromatin interactions |
ENSG00000234143 | chromatin interactions |
ENSG00000227802 | chromatin interactions |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs546503927 | chr2:234655067-234655068 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 3 gene(s) | Overlapped CNVs | n/a |
2 | rs141272199 | chr2:234655076-234655077 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 3 gene(s) | Overlapped CNVs | n/a |
3 | rs538596800 | chr2:234655117-234655118 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 3 gene(s) | Overlapped CNVs | n/a |
4 | rs371846977 | chr2:234655139-234655140 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
5 | rs536618082 | chr2:234655141-234655142 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
6 | rs4663968 | chr2:234655144-234655145 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
7 | rs575149330 | chr2:234655184-234655185 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
8 | rs567530423 | chr2:234655200-234655201 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
9 | rs537470722 | chr2:234655216-234655217 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
10 | rs553124614 | chr2:234655286-234655287 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
11 | rs375179260 | chr2:234655293-234655294 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
12 | rs4663333 | chr2:234655303-234655304 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | LD-proxies of rSNPOverlapped rCNV | n/a |
13 | rs4663969 | chr2:234655313-234655314 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
14 | rs192486679 | chr2:234655333-234655334 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
15 | rs575730371 | chr2:234655334-234655335 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | TF binding regionChromatin interactive region | 6 gene(s) | Overlapped CNVs | n/a |
16 | rs544593514 | chr2:234655516-234655517 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
17 | rs561454270 | chr2:234655526-234655527 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
18 | rs185798867 | chr2:234655582-234655583 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
19 | rs35269037 | chr2:234655612-234655613 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
20 | rs118160610 | chr2:234655622-234655623 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
21 | rs560743202 | chr2:234655637-234655638 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
22 | rs563411016 | chr2:234655652-234655653 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
23 | rs532529523 | chr2:234655759-234655760 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | CpG islandChromatin interactive region | 5 gene(s) | Overlapped CNVs | n/a |
24 | rs28946888 | chr2:234655776-234655777 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
25 | rs35672427 | chr2:234655782-234655783 | Weak transcription Flanking Active TSS Enhancers Bivalent Enhancer | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
26 | rs145059616 | chr2:234655805-234655806 | Weak transcription Flanking Active TSS Enhancers | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
27 | rs559745186 | chr2:234655810-234655811 | Weak transcription Flanking Active TSS Enhancers | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
28 | rs189112981 | chr2:234655833-234655834 | Weak transcription Flanking Active TSS Enhancers | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
29 | rs375624902 | chr2:234655844-234655845 | Weak transcription Flanking Active TSS Enhancers | Chromatin interactive region | 2 gene(s) | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Ependymoma | 16718352 | CNVD |
Melanoma | 18172304 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Breast cancer | 17603634 | CNVD |
Breast cancer | 16272173 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Autism | 16446308 | CNVD |
Autism | 19401682 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Lung cancer | 18438408 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Biliary cancer | 20360734 | CNVD |
Breast cancer | 20360734 | CNVD |
Coronary artery disease | 20360734 | CNVD |
Crohn''s disease | 20360734 | CNVD |
Hypertension | 20360734 | CNVD |
Rheumatoid arthritis | 20360734 | CNVD |
Type 1 diabetes | 20360734 | CNVD |
Type 2 diabetes | 20360734 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Cervical cancer | 21062161 | CNVD |
Adenoid cystic carcinoma | 18698036 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Chordoma | 18071362 | CNVD |
Developmental delay | 21147756 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Cancer | 22429812 | CNVD |
Bladder cancer | 21909424 | CNVD |
Renal cell carcinoma | 21668985 | CNVD |
Breast cancer | 21785460 | CNVD |
Prostate cancer | 18632612 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Wilms tumour | 21544195 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
prenatal diagnosis | 22389664 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Mental retardation | 20152051 | CNVD |
Cancer | 21183584 | CNVD |
Albright''s disease | 22277900 | CNVD |
Brachydactyly-Mental Retardation Syndrome | 22470819 | CNVD |
T-cell acute lymphoblastic leukemia | 18185524 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Autism | 18414403 | CNVD |
Chronic myeloid leukemia | 21384125 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:234620400-234659200 | Weak transcription | Colonic Mucosa | Colon |
2 | chr2:234626600-234668400 | Weak transcription | NHEK | skin |
3 | chr2:234646400-234666600 | Weak transcription | Stomach Mucosa | stomach |
4 | chr2:234649800-234658800 | Weak transcription | Rectal Mucosa Donor 29 | rectum |
5 | chr2:234652800-234658200 | Weak transcription | Foreskin Keratinocyte Primary Cells skin03 | Skin |
6 | chr2:234652800-234659200 | Weak transcription | Foreskin Keratinocyte Primary Cells skin02 | Skin |
7 | chr2:234653200-234655600 | Enhancers | Fetal Intestine Small | intestine |
8 | chr2:234654200-234655400 | Enhancers | Duodenum Mucosa | Duodenum |
9 | chr2:234654200-234655400 | Enhancers | Fetal Intestine Large | intestine |
10 | chr2:234654400-234656000 | Flanking Active TSS | Liver | Liver |
11 | chr2:234654600-234655800 | Bivalent Enhancer | HepG2 | liver |
12 | chr2:234655000-234655200 | Flanking Active TSS | A549 | lung |
13 | chr2:234655000-234655600 | Enhancers | Gastric | stomach |
14 | chr2:234655200-234655400 | Enhancers | A549 | lung |
15 | chr2:234655400-234655600 | Flanking Active TSS | A549 | lung |
16 | chr2:234655400-234656200 | Enhancers | Pancreas | Pancrea |
17 | chr2:234655600-234656200 | Enhancers | A549 | lung |